Abstract
The programmed death ligand-1 (PD-L1) expression is an important biomarker in the era of immunotherapy using immune checkpoint inhibitors. PD-L1 testing using the 22C3 antibody (Ab) has been the standard in determining the first-line therapy in advanced non-small cell lung cancer (NSCLC). Atezolizumab monotherapy has become a first-line treatment option based on the IMpower 110 trial result. However, there are few data on the effectiveness of PD-L1 staining using SP142 Ab.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
